INDRAPRASTHA MEDICAL share price has plunged 4% and is presently trading at Rs 414.2.
Meanwhile, the BSE HEALTHCARE index is at 43,546.8 (up 1.0%).
Among the top losers in the BSE HEALTHCARE index today are Biocon (down 2.0%) and ASTRAZENECA PHARMA (down 0.8%).
Cipla (up 8.2%) and POLY MEDICURE (up 3.7%) are among the top gainers today.
Over the last one year, INDRAPRASTHA MEDICAL has moved up from Rs 157.9 to Rs 414.2, registering a gain of Rs 256.4 (up 162.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 43,546.8, registering a gain of 59.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 196.9%), SUVEN PHARMACEUTICALS (up 125.6%) and Glenmark Pharma (up 124.6%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,683.1 (down 0.3%).
The top losers among the BSE Sensex today are Tech Mahindra (down 2.7%) and TCS (down 1.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,256.0 (down 0.4%). Tech Mahindra and TCS are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 79,683.1, registering a gain of 15,570.4 points (up 24.3%).
INDRAPRASTHA MEDICAL net profit grew 29.1% YoY to Rs 424 million for the quarter ended September 2024, compared to a profit of Rs 329 million a year ago. Net sales rose 10.4% to Rs 3,498 million during the period as against Rs 3,170 million in July-September 2023.
For the year ended March 2024, INDRAPRASTHA MEDICAL reported 43.9% increase in net profit to Rs 1,240 million compared to net profit of Rs 862 million during FY23. Revenue of the company grew 13.3% to Rs 12,447 million during FY24.
The current Price to earnings ratio of INDRAPRASTHA MEDICAL, based on rolling 12 month earnings, stands at 25.7.
Equitymaster requests your view! Post a comment on "INDRAPRASTHA MEDICAL Plunges 4%; BSE HEALTHCARE Index Up 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!